The Most-Popular Center for Biosimilars® Interviews of 2020

December 26, 2020

Here are some of our most-popular biosimilar interviews for all of 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are some of our most-popular biosimilar interviews for all of 2020.

Soumi Saha, PharmD, JD, senior director of advocacy at Premier, discusses drug shortages caused by coronavirus disease 2019 (COVID-19) and policy recommendations that could fix the problem.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, explains potential consequences if the United States were to do away with biosimilars.

Will Gatziolis, MBA, an associate principal at ZS, explains how the COVID-19 pandemic will help biosimilar uptake and what manufacturers can do to take advantage of this opportunity.

Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market, at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.

An additional interview features Byoungseo Choi, head of marketing for Celltrion Healthcare, who discussed how Celltrion's infliximab biosimilar can aid in the treatment of COVID-19–related inflammation, as well as the company’s launch plans for biosimilars through 2030.

To read all these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Interviews

x